Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC53H56N10O6S |
InChIKeyVKIHBXFTEAZOLM-NPSGEOLXSA-N |
CAS Registry- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 24 Dec 2022 |





